Coeptis <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Subsidiary SNAP Biosciences Enters Licensing Partnership with Monarch Therapeutics to Enhance SNAP-CAR NK Cell Therapy in Oncology
Coeptis Therapeutics Holdings Inc., through its subsidiary SNAP Biosciences, Inc., has entered into a licensing agreement with Monarch Therapeutics Inc. to enhance the development of its SNAP-CAR NK cell therapy platform in oncology. This partnership grants SNAP Biosciences access to Monarch's innovative small-molecule adaptor technology, broadening the functionality of the Snap-Car universal CAR-based receptor platform. The collaboration aims to advance the precision, flexibility, and scalability of NK therapies, targeting multiple tumor antigens and addressing challenges in oncology treatment. Monarch Therapeutics will receive upfront licensing payments, potential development milestone payments, and royalties on net sales as part of the agreement. This initiative is expected to transform outcomes for patients with difficult-to-treat cancers.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coeptis Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9458972-en) on May 28, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。